Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.38 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392096 | 0.86 | MAP2K1 (0.51) | L3MBTL1 | |
| SCHEMBL393028 | 0.77 | MAPT (0.44) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL4340818 | 0.72 | RAB9A (0.39) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4340927 | 0.71 | AURKA (0.38) | ALDH1A1MEN1KMT2AKDM4ETP53 | |
| SCHEMBL4322051 | 0.68 | KDM4E (0.42) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL4329913 | 0.68 | KDM4E (0.43) | ALDH1A1KDM4ETP53SMN1; SMN2RAB9A | |
| SCHEMBL27780666 | 0.68 | KDM4E (0.41) | ALDH1A1KMT2AKDM4ELMNATP53 | |
| SCHEMBL28289322 | 0.67 | KDM4E (0.51) | ALDH1A1KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1341502 | 0.67 | KDM4E (0.47) | ALDH1A1GAAMEN1KMT2AKDM4E | |
| SCHEMBL1342361 | 0.67 | CSF1R (0.41) | ALDH1A1MEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364973-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8299076-B2 | crystalline form of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; for hyperproliferative diseases, such as cancer and inflammation in mammals; crystallization under acidic condition | ARRAY BIOPHARMA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8211920-B2 | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8101639-B2 | 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1922307-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110288092-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7732616-B2 | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1723/4885GAA 2737/4885MEN1 1716/4885 |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | BRAF, NRAS, MAP3K1 | ALDH1A1 2121/4885GAA 2860/4885MEN1 2222/4885 |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ALDH1A1 1723/4885GAA 2737/4885MEN1 1716/4885 |
| US-20090215834-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ALDH1A1 1533/4885GAA 3004/4885MEN1 1535/4885 |
| US-20110288092-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, RAF1 | ALDH1A1 1827/4885GAA 2893/4885MEN1 1522/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | ALDH1A1 1827/4885GAA 2893/4885MEN1 1522/4885 |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, CDK9 | ALDH1A1 2030/4885GAA 3965/4885MEN1 2098/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | ALDH1A1 1992/4885GAA 2856/4885MEN1 1888/4885 |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | ALDH1A1 1327/4885GAA 3162/4885MEN1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.